Rani Therapeutics Holdings, Inc. Class A Share Price
RANIRani Therapeutics Holdings, Inc. Class A Stock Performance
Open $1.10 | Prev. Close $1.07 | Circuit Range N/A |
Day Range $1.06 - $1.10 | Year Range $0.39 - $3.85 | Volume 5,487 |
Average Traded $1.07 |
Rani Therapeutics Holdings, Inc. Class A Share Price Chart
About Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Rani Therapeutics Holdings, Inc. Class A Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-May-26 | $0.91 | $1.09 | +23.03% |
19-May-26 | $0.93 | $0.89 | -7.39% |
18-May-26 | $1.06 | $0.96 | -11.83% |
15-May-26 | $1.10 | $1.09 | -1.80% |
14-May-26 | $1.06 | $1.11 | +4.72% |
13-May-26 | $1.05 | $1.06 | -4.50% |
12-May-26 | $1.03 | $1.11 | +3.26% |